THERMO FISHER SCIENTIFIC INC. — Form 8-K
Filed July 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 28/100
What the filing says
Thermo Fisher reported Q2 2026 revenue of $11.99B (10% YoY growth, 5% organic), with GAAP diluted EPS of $4.68 (9% growth) and adjusted EPS of $6.03 (13% growth). The company repurchased $1.0B of stock during the quarter and announced the divestiture of its microbiology business. Adjusted operating margin expanded 90 basis points to 22.8%, with all four segments showing revenue and margin growth.
Why this rating
Solid operational performance with organic growth of 5% and margin expansion is ordinary execution for a $154B company. Quarter-to-quarter earnings beats are routine; no transformational events, acquisitions, or guidance changes disclosed—only routine capital deployment.
See more from July 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.